Pluriomics expands its presence in the USA
Leiden, The Netherlands, Gosselies, Belgium, 3rd April, 2017 –
Pluriomics, an emerging Belgian/Dutch biotechnology company whose mission is to deliver cardiac drug discovery and safety solutions based on its best-in-class human iPSC-derived cardiomyocyte technology, today announced that expands its USA operations to better serves its clients in North America.
Pluriomics is a leading expert in human cardiovascular stem cell technology, disease modeling and cell-based assays development for cardiovascular drug discovery. Pluriomics commercializes worldwide its proprietary Pluricyte® Cardiomyocytes, Pluricyte® Cardiomyocyte Medium and Pluricyte® Cardiomyocyte Differentiation Kit and cardiac drug discovery services as well. Pluriomics lead product, Pluricyte® Cardiomyocytes are fully functional human iPSC-derived cardiomyocytes exhibiting unique electrophysiological characteristics that make them exceptionally well-suited for implementation in contractility-, biochemistry- and electrophysiology-based assays to improve drug safety and efficacy screenings.
hiPSC-derived cardiomyocyte market increased dramatically the past years especially in the safety domain. This trend is confirmed by the Comprehensive In Vitro Proarrhythmia Assay (CiPA), an initiative driven by the Food and Drug Administration (FDA) which aims to evaluate hiPSC-derived cardiomyocytes as a new model to replace current methods to assess and better predict proarrhythmic risk of drugs candidates.
Pluriomics will meet this growing demand, expanding further its USA operations to improve the availability of its unique cardiovascular products including its proprietary Pluricyte® Cardiomyocytes in North America. This is in line with Pluriomics strategy to be close to its customers and to develop its business worldwide in order to become the major actor in cardiac drug development.
Stefan Braam, CEO of Pluriomics BV, commented: “the US market is rapidly growing and we have to deal with significant increase in our activities in North America. The addition of operational and logistic capabilities for our products in the US adds critical abilities for Pluriomics to develop its business further across the Atlantic.”
For more information please contact:
+31 (0)71 332 2230
Pluriomics, a leading expert in human cardiovascular stem cell technology, manufactures fully functional human induced pluripotent stem cell derived cardiomyocytes (Pluricyte® Cardiomyocytes) using well-defined, serum-free medium that enhances the maturation and function of the cells. Pluriomics’ Pluricyte® Cardiomyocytes and innovative technologies are exceptionally well suited for implementation in various stages of drug discovery to improve decision-making, reduce attrition rates and provide an alternative for animal testing.
Pluriomics offers unique cardiac drug discovery and safety assessment solutions based on its best-in-class human iPSC-derived cardiomyocyte cellular assays. The company aims to contribute to the efficiency of the drug discovery and development process by delivering products and services for early discovery and safety assessment.
The company is backed by private investors, Venture Funds and strategic investment from regional investment funds (Vesalius Biocapital, InnovationQuarter, S.R.I.W, SambrInvest, SFPI-FPIM).
Pluriomics is based in Leiden, The Netherlands and in Gosselies, Belgium.
For more information please visit www.pluriomics.com
To view this press release as a PDF file, click here